Phase 1

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Alkermes) ALKS 4230-001 / ARTISTRY-2A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors- ARTISTRY-2 (001)Juergens, Dr RosalynOpen to recruitmentNCT03861793
(Fusion) FPX-01-01A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid TumoursJuergens, Dr RosalynOpen to recruitmentNCT03746431
(Merck) MK-1084-001A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid TumorsJuergens, Dr RosalynOpen to recruitmentNCT05067283
(Merck) MK-4830-001A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid TumorsHotte, Dr SebastienOpen to recruitmentNCT03564691
(SignalChem) SLC-391-101A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study of the Safety and Pharmacokinetics of the AXL Inhibitor SLC-391 Administered Orally to Subjects with Solid TumoursHotte, Dr SebastienOpen to recruitmentNCT03990454
Download PDF